Hepatology

Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?

A 24-week anti-PD-1 antibody regimen reduced HBsAg and enhanced HBV-specific T cell responses in patients with chronic hepatitis B, offering a potential functional cure strategy.

ACLF: Why G-CSF works for some, but fails others

Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.

MASH: Why diabetes management now demands a liver-first approach?

Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.

Seladelpar and elafibranor: second-line options for PBC

For patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid, seladelpar and elafibranor offer new therapeutic avenues.

Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?

Annual surveillance for cholangiocarcinoma in primary sclerosing cholangitis patients should include noninvasive imaging and serum CA 19-9, according to expert recommendations.

Why primary sclerosing cholangitis remains a therapeutic graveyard

Despite numerous attempts, no disease-modifying therapy has succeeded in primary sclerosing cholangitis, leaving transplant as the only definitive treatment.

Pruritus in primary biliary cholangitis: the symptom that drives quality of life

Pruritus significantly impacts quality of life in primary biliary cholangitis, driving patient-reported outcomes and necessitating targeted management strategies.

Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails

Seladelpar and elafibranor offer new therapeutic avenues for primary biliary cholangitis patients with inadequate response to ursodeoxycholic acid.

Coffee may cut liver disease risk, related mortality

Regular coffee consumption correlates with a reduced risk of chronic liver disease and associated mortality, according to UK Biobank data.